CD8A and neoplasm: The CCR2 antagonist, combined with low-dose sorafenib, potentiated anti-liver tumor effects via upregulating intratumoral CD8+ T cells and enhanced the distribution of CD8+ T cells in the tumor milieu, without obvious toxicity [147].